drugset / Trial / NCT04140396

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

NCT04140396 ↗

Phase 4 Terminated 1 enrolled Stanford University
RandomizedParallel-groupSingle-blindTreatment

Summary

The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of delirium. In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that IVL is overall well tolerated and have shown other beneficial effects such as anti-inflammatory properties. To this date, there have been no published randomized clinical trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture pain. Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours compared to placebo in adult patients with acute traumatic rib fractures.

Timeline

Start
2020-02-10
Primary completion
2020-11-09
Completion
2020-11-09

Outcome

Outcome not reported

Stopped (Business): “Lack of personnel and lack of funding for the study drug”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 1 mg/kg Intravenous

Indications

No indication recorded.